Mupadolimab vs Oleclumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline
Mupadolimab
Developed by Corvus Pharmaceuticals and partners
NCT03454451 · Phase 1 · completed
Although the registry labels the allocation as randomized, none of the six groups received a placebo or an inactive comparator, and there was no blinding, so this functions as an open-label dose-escalation and combination study rather than a controlled comparison. The main goals were safety, tolerated dose, and drug levels. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. (From start of treatment to end of treatment, up to 36 months); Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab. (From start of treatment to end of treatment, up to 36 months); Identify the MDL(maximum dose level) of single agent CPI-006 (From start of treatment to end of treatment, up to 36 months): Mupadolimab (CPI-006) monotherapy/combination in advanced cancers: doses up to 18 mg/kg tolerated without DLTs; minor tumor regression (below PR threshold) in 5 patients with prior PD.
Result source: NCT03454451
Oleclumab
Developed by MedImmune LLC
NCT03822351 · Phase 2 · completed
Participants were randomized among three treatment groups, including durvalumab monotherapy as the comparator, but the study was open-label rather than blinded; 60 participants received durvalumab plus oleclumab and 67 received durvalumab alone. The clinical primary endpoint, RECIST 1.1 objective response rate, was numerically higher with oleclumab, but statistical significance of the comparison was not reported, so the result remains unclear.
Next expected readout: January 2027 · NCT05221840 (registry estimate)
Reported efficacy
Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Control Arm (Durvalumab Monotherapy) 23.9% (95% CI 14.3-35.9) vs Arm A (Durvalumab + Oleclumab) 35.0% (95% CI 23.1-48.4) vs Arm B (Durvalumab + Monalizumab) 40.3% (95% CI 28.1-53.6) (unclear)
Result source: NCT03822351
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Mupadolimab | Oleclumab |
|---|---|---|
| PFS, median | —Not reported | 21.1 vs 7.3vs Durvalumab MonotherapyNCT03822351 |
| OS, median | —Not reported | —Trial running · NCT05221840 |
| ORR | —Not reported | 35% vs 23.9%vs Durvalumab MonotherapyNCT03822351 |
| Duration of response, median | —Not reported | 29.9NCT03822351 |
PFS, median
- Mupadolimab
- —Not reported
- Oleclumab
- 21.1 vs 7.3vs Durvalumab MonotherapyNCT03822351
OS, median
- Mupadolimab
- —Not reported
- Oleclumab
- —Trial running · NCT05221840
ORR
- Mupadolimab
- —Not reported
- Oleclumab
- 35% vs 23.9%vs Durvalumab MonotherapyNCT03822351
Duration of response, median
- Mupadolimab
- —Not reported
- Oleclumab
- 29.9NCT03822351
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Mupadolimab: 0 of 4 rows · Oleclumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Oleclumab |
|---|---|
| Dropout rate | 51.7%Arm A (Durvalumab + Oleclumab)a NCT03822351 · Phase 2 · combination show 3 more results—Durvalumab + Oleclumab NCT03822351 · Phase 2 · combination 3.7%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 14.3%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Arm A (Durvalumab + Oleclumab)a NCT03822351 · Phase 2 · combination show 3 more results—Durvalumab + Oleclumab NCT03822351 · Phase 2 · combination —1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence —1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —Arm A (Durvalumab + Oleclumab)a NCT03822351 · Phase 2 · combination show 3 more results33.9%Durvalumab + Oleclumab NCT03822351 · Phase 2 · combination 11.5%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 9.5%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 2 more results1500 mg fatigue 23.1% procedural pain 19.2% asthenia 11.5% NCT03794544 · Phase 2 · registry result, not featured evidence 1500 mg + 3000 mg fatigue 19% asthenia 14.3% cough 14.3% NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Oleclumab
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mupadolimab's landscape · Oleclumab's landscape